Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers 2021

Michael Heller's Biography



Michael Heller, Distinguished Scientist - Knight Cancer Institute at Oregon Health & Science University (OHSU), Center for Cancer Early Detection and Research (CEDAR); Professor, University of California-San Diego

Michael J. Heller received his PhD in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. From 1976 to 1984 he was supervisor of the DNA Technology Group at Amoco Corporation (Standard Oil Indiana) During that time he carried out early bioengineering and recombinant DNA work on plants, algae and photosynthetic bacteria for energy and chemical production, and developed some of the first fluorescent resonant energy transfer (FRET) and chemiluminescent oligonucleotide probes for DNA hybridization analysis. He also oversaw Amoco’s sponsored energy and chemical research work at Cetus Corporation, which included the cloning of thermophilic enzymes. Dr. Heller was the Director of Molecular Biology at Molecular Biosystems, Inc., from 1984 to 1987. He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer from 1987 to 1989. He was a co-found of Nanogen, and served as the Chief Technical Officer from 1993 to 2001. Nanogen carried out the successful development and commercialization of electronic DNA microarray technology for clinical diagnostic genotyping applications. Dr. Heller is a Professor (Recall/Emeritus) in the Departments of Nanoengineering and Bioengineering at the University California San Diego. He is also now a Distinguished Scientist at the Oregon Health & Science University (OHSU), Center for Cancer Early Detection and Research (CEDAR), in Portland, Oregon. He has also co-founded a company called Biological Dynamics which is developing new sample to answer cancer diagnostics technology, based on the novel dielectrophoretic (DEP) technology developed at his UCSD lab. Dr. Heller has extensive industrial experience in biotechnology, biomedical and molecular diagnostic devices and nanotechnology, with particular expertise in the areas of DNA probe diagnostics, electrokinetic lab-on-a-chip devices, DNA synthesis, FRET/fluorescent-based detection technologies and electric field assisted self-assembly of DNA nanostructures. Dr. Heller has over 100 publications and 56 issued US patents.

Michael Heller Image

Proteases – A Promising and Untapped Group of Protein Biomarkers for a Wide Range of Disease Diagnostics

Friday, 26 February 2021 at 14:30

Add to Calendar ▼2021-02-26 14:30:002021-02-26 15:30:00Europe/LondonProteases – A Promising and Untapped Group of Protein Biomarkers for a Wide Range of Disease DiagnosticsCirculating Biomarkers 2021 in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com

Proteases represent a large class of enzymes that degrade proteins and have been associated with a wide range of diseases. These include: cardiovascular diseases; coagulation disorders; inflammatory diseases, diabetes, sepsis; infectious diseases and cancer. While proteases have seen some limited use in disease diagnostics, their full potential has not been exploited. Also, in most cases there detection is carried out using classical immunofluorescent antibody-protein binding reactions. Because they are catalyst which rapidly convert specific substrates into products, they offer an added advantage for signal amplification. At our UCSD lab we have capitalized on this property and developed rapid sample to answer protease assays based on fluorescent charge-changing peptide substrates. These assays can be carried our using very small volumes (5ul-10ul) of whole blood samples. No sample preparation is required and the fluorescent peptide products can be detected in about 30 minutes using simple mini-gel electrophoretic formats. By way of just one example we have shown elevated digestive proteolytic activity in the peripheral blood of individuals with Type-2 Diabetes. More recently we have preliminary results indicating the elevation of specific proteases in various cancers. The ultimate goal is to use our rapid charge-changing fluorescent peptide technology to fully exploit the promise of protease biomarkers for disease diagnostics, including cancer.


Add to Calendar ▼2021-02-25 00:00:002021-02-26 00:00:00Europe/LondonCirculating Biomarkers 2021Circulating Biomarkers 2021 in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com